This application is being submitted by Loyola University Chicago, Stritch School of Medicine, Cardinal Bernardin Cancer Center for renewal of this institution's long-standing participation as a site for the conduct of clinical trials under the umbrella of the Southwest Oncology Group (SWOG). Loyola remains a highly productive member of SWOG, enrolling 674 subjects to SWOG studies over the past 5 year grant cycle. Twenty-one members of the Division of Hematology/Oncology faculty are members of SWOG. Loyola's Departments of Radiation Oncology, Surgery, Thoracic Surgery, Urology, Gynecology and Pathology are active participants in SWOG-sponsored studies, identifying patients for inclusion in SWOG studies and for the subsequent treatment of these patients. The Clinical Research Office of the Cancer Center consists of 11 Registered Nurses, 4 Protocol Coordinators and 1 Regulatory Data Coordinator, who coordinate approximately 150 total clinical trials for all of the above disciplines. Loyola has four affiliate institutions participation in SWOG studies: Good Samaritan Hospital in Downers Grove, Illinois;Central DuPage Hospital in Winfield, Illinois, Edward Hospital in Naperville, Illinois, and Quad Cities CGOP in Davenport, lowa. Plans are underway to increase our commitment to SWOG during the next grant cycle both by increasing accruals with additional planned affiliates and increasing our scientific participation.

Public Health Relevance

The Southwest Oncology Group is one of the NCI's CTEP-supported cooperative groups which seek new and more effective therapies for cancer. PRINCIPAL INVESTIGATOR: Dr. Stiff is an experienced clinical researcher with a long-term commitment to SWOG programs. He is fully qualified for his role on this application. PROTECTION OF HUMAN SUBJECTS (Resume): ACCEPTABLE No concerns are evident. INCLUSION OF WOMEN PLAN (Resume): ACCEPTABLE Women account for 63% of all enrollments. No concerns are evident. INCLUSION OF MINORITIES PLAN (Resume): ACCEPTABLE Minority accrual could be improved. Hispanics represent 10% of accruals and African-Americans represent only 3% of accruals. They report a series of important efforts to increase accrual of minority populations including development of a position for a community outreach coordinator, the work of a physician liaison to the Hispanic community, the use of short form consents for non-English speakers, the use of patient navigators, the provision of low cost screening breast studies for the medically underserved, and offering studies to a broad geography across the Chicago area. Additional planning efforts to increase minority accrual are needed. INCLUSION OF CHILDREN PLAN (Resume): ACCEPTABLE Enrolled subjects are generally 18 years of age or older. OVERALL RECOMMENDATION: This application is rated 24 and is recommended for six years of support.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA046282-23
Application #
7767336
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1988-01-01
Project End
2015-12-31
Budget Start
2010-03-30
Budget End
2010-12-31
Support Year
23
Fiscal Year
2010
Total Cost
$338,795
Indirect Cost
Name
Loyola University Chicago
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
791277940
City
Maywood
State
IL
Country
United States
Zip Code
60153
Mongiovi, Jennifer M; Zirpoli, Gary R; Cannioto, Rikki et al. (2018) Associations between self-reported diet during treatment and chemotherapy-induced peripheral neuropathy in a cooperative group trial (S0221). Breast Cancer Res 20:146
Stiff, Patrick J; Montesinos, Pau; Peled, Tony et al. (2018) Cohort-Controlled Comparison of Umbilical Cord Blood Transplantation Using Carlecortemcel-L, a Single Progenitor-Enriched Cord Blood, to Double Cord Blood Unit Transplantation. Biol Blood Marrow Transplant 24:1463-1470
Messing, Edward M; Tangen, Catherine M; Lerner, Seth P et al. (2018) Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. JAMA 319:1880-1888
Smith, Eileen P; Li, Hongli; Friedberg, Jonathan W et al. (2018) Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703). Biol Blood Marrow Transplant 24:700-707
West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Persky, Daniel O; Li, Hongli; Rimsza, Lisa M et al. (2018) A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. Am J Hematol 93:486-493
Statler, Abby; Othus, Megan; Erba, Harry P et al. (2018) Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies. Blood 131:2782-2788
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585

Showing the most recent 10 out of 238 publications